Hippel James, the Chief Financial Officer of Bio-Techne Corp, has made significant stock transactions as detailed in an amended filing with the SEC. This update is crucial as it highlights changes in beneficial ownership, which can impact both the company and the broader industry.

Background

Bio-Techne Corp, identified by its CIK 0000842023, operates in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company is based in Minneapolis, Minnesota, and has been active in filing various reports with the SEC, including recent submissions that reflect ongoing changes in stock ownership.

What the Filing Says

The amended filing, submitted on November 2, 2026, outlines transactions that occurred on August 15, 2026. It includes the acquisition of 9,980 shares of common stock without a purchase price listed, indicating a direct ownership increase. Additionally, 4,423 shares were acquired at a price of $72.40 per share. Following these transactions, Hippel James now holds 174,694 shares of common stock.

Impact

This filing may affect various stakeholders, including shareholders and potential investors, as it reflects the CFO's confidence in the company’s future. The biological products industry, where Bio-Techne operates, may also see shifts as competitors analyze these developments and adjust their strategies accordingly.

What's Next

The filing does not say what happens next.